Boryung Pharmaceutical Co., Ltd
Boryung Pharmaceutical Co., Ltd
Explore linked clinical trials.32 results · Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| To Evaluate the Renal Protective Effects and Safety of 'Fimasartan and Atorvastatin' or 'Fimasartan, Atorvastatin and Ezetimibe'. | cardiovascular disorder, essential hypertension, hypertensive disorder, vascular disorder | Not yet recruiting | Not stated | 2026-07-06 | NCT07685054 | |
| Lenvatinib or Regorafenib for Advanced Hepatocellular Carcinoma After Immunotherapy (REVIVE) | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm | Not yet recruiting | Phase 2 | 2026-05-27 | NCT07495579 | |
| Trastzumab Deruxtecan Versus SOC in Recurrent Ovarian That Progressed on Prior PARP Inhibitor Therapy | Adnexal Diseases, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Urogenital Diseases, Urogenital Neoplasms, endocrine system disorder, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder | Recruiting | Phase 2 | 2026-04-20 | NCT07340164 | |
| Dapagliflozin for Anemia in Lower-Risk Myelodysplastic Syndromes | Hemic and Lymphatic Diseases, anemia, bone marrow disorder, hematologic disorder, myelodysplastic syndrome | Not yet recruiting | Phase 2 | 2026-04-08 | NCT07516847 | |
| Regorafenib After Treatment Failure of First Line Immune Checkpoint Inhibitor Treatment in Advanced Hepatocellular Carcinoma Patients | Digestive System Diseases, Digestive System Neoplasms, Disease Attributes, Disease Progression, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm | Not yet recruiting | Phase 2 | 2026-04-07 | NCT07514455 | |
| Regorafenib After Failure of Lenvatinib in Patients With Unresectable HCC: The RELEVANT-HCC Trial | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm | Not yet recruiting | Phase 2 | 2026-04-07 | NCT07514429 | |
| Adjuvant mFOLFIRINOX for High-risk Stage III Colon Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colonic neoplasm, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm | Recruiting | Phase 2 / Phase 3 | 2026-03-19 | NCT05179889 | |
| A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-3 and BR1015-2 Under Fed Conditions | cardiovascular disorder, essential hypertension, hypertensive disorder, vascular disorder | Not yet recruiting | Phase 1 | 2026-02-19 | NCT07421414 | |
| A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-3 and BR1015-2 Under Fasting Conditions | cardiovascular disorder, essential hypertension, hypertensive disorder, vascular disorder | Not yet recruiting | Phase 1 | 2026-02-19 | NCT07421401 | |
| A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-1 and BR1015-2 Under Fed Conditions | cardiovascular disorder, essential hypertension, hypertensive disorder, vascular disorder | Not yet recruiting | Phase 1 | 2026-02-19 | NCT07421388 | |
| A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-1 and BR1015-2 Under Fasting Conditions | cardiovascular disorder, essential hypertension, hypertensive disorder, vascular disorder | Not yet recruiting | Phase 1 | 2026-02-19 | NCT07421375 | |
| A Study of BR1400-1, BR1400-2, BR1400-3, BR1400-4, and BR1400-5 in Patients With Essential Hypertension | cardiovascular disorder, essential hypertension, hypertensive disorder, vascular disorder | Not yet recruiting | Phase 2 | 2026-01-28 | NCT07373613 | |
| A Study of Bosmolisib (BR101801) in Participants With R/R PTCL. | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, T-cell non-Hodgkin lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mature T-cell and NK-cell non-Hodgkin lymphoma, neoplasm | Not yet recruiting | Phase 2 | 2026-01-28 | NCT07180771 | |
| A Study of Olanzapine in Participants With Bipolar Disorder. | Bipolar and Related Disorders, bipolar disorder, mood disorder, psychiatric disorder | Recruiting | Not stated | 2025-12-04 | NCT07263191 | |
| A Study of Second- and Later-line Palliative Chemotherapy in Patients With Metastatic Colorectal Cancer. | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Recruiting | Not stated | 2025-12-04 | NCT07263178 | |
| Observational Study to Evaluate the Safety and Efficacy of Zepzelca™ Injection | SCLC | Recruiting | Not stated | 2025-09-16 | NCT06021483 | |
| A Phase IV Clinical Trial to Compare the Efficacy and Safety of Metformin+Sodium-Glucose Cotransporter 2 Inhibitor(SGLT2-i)+Thiazolidinedione (TZD) in Patients With Type 2 Diabetes | Nutritional and Metabolic Diseases, diabetes mellitus, endocrine system disorder, glucose metabolism disease, metabolic disease, type 2 diabetes mellitus | Recruiting | Phase 4 | 2025-09-15 | NCT06972732 | |
| A Clinical Trial to Evaluate the Safety and Efficacy of Olanzapine Titration Schedule in Patients With Schizophrenia | Schizophrenia Spectrum and Other Psychotic Disorders, psychiatric disorder, schizophrenia | Recruiting | Phase 2 | 2025-09-15 | NCT06821945 | |
| A Study to Evaluate the Efficacy and Safety of Dapagliflozin in Patient With Type 2 Diabetes Mellitus and Hypertension | Nutritional and Metabolic Diseases, cardiovascular disorder, diabetes mellitus, endocrine system disorder, glucose metabolism disease, hypertensive disorder, metabolic disease, vascular disorder | Recruiting | Not stated | 2025-09-15 | NCT05970237 | |
| A Study to Evaluate Ethanol-induced Symptoms and Safety in Breast Cancer Patients | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Not stated | 2025-09-12 | NCT06537752 | |
| A Study to Evaluate the Efficacy and Safety of Fixed-Dose Combination of Pitavastatin/Ezetimib | Mixed Dyslipidemia; Primary Hypercholesterolemia | Recruiting | Not stated | 2025-09-12 | NCT06314919 | |
| An OS to Evaluate Effectiveness and Safety of Fixed-dose Combinations of FMS/AML or FMS/AML/HCTZ | cardiovascular disorder, essential hypertension, hypertensive disorder, vascular disorder | Recruiting | Not stated | 2025-09-12 | NCT05413057 | |
| Oxaliplatin Adjuvant Chemotherapy After Curative Resection of Primary Colon Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colonic neoplasm, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm | Active, not recruiting | Not stated | 2025-09-12 | NCT04416490 | |
| A Study to Evaluate the Pharmacokinetics and Safety Between "BR3006" and Co-administration of "BR3006A", "BR3006B", and "BR3006C" in Healthy Adult Volunteers (Fed) | Nutritional and Metabolic Diseases, diabetes mellitus, endocrine system disorder, glucose metabolism disease, metabolic disease | Recruiting | Phase 1 | 2025-07-24 | NCT07083401 | |
| A Study to Evaluate the Pharmacokinetics and Safety Between "BR3006" and Co-administration of "BR3006A", "BR3006B", and "BR3006C" in Healthy Adult Volunteers (Fasting) | Nutritional and Metabolic Diseases, diabetes mellitus, endocrine system disorder, glucose metabolism disease, metabolic disease | Recruiting | Phase 1 | 2025-07-24 | NCT07083388 |